What is Cardiff Oncology Market Cap?
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cardiff Oncology's share price for the quarter that ended in Mar. 2024 was $5.34. Cardiff Oncology's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 44.71 Mil. Therefore, Cardiff Oncology's market cap for the quarter that ended in Mar. 2024 was $238.75 Mil.
Cardiff Oncology's quarterly market cap increased from Sep. 2023 ($62.10 Mil) to Dec. 2023 ($66.12 Mil) and increased from Dec. 2023 ($66.12 Mil) to Mar. 2024 ($238.75 Mil).
Cardiff Oncology's annual market cap declined from Dec. 2021 ($252.20 Mil) to Dec. 2022 ($62.55 Mil) but then increased from Dec. 2022 ($62.55 Mil) to Dec. 2023 ($66.12 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cardiff Oncology's Enterprise Value for Today is $54.26 Mil.
Cardiff Oncology Market Cap Historical Data
The historical data trend for Cardiff Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cardiff Oncology Market Cap Chart
| Cardiff Oncology Annual Data | ||||||||||||||||||||
| Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
| Market Cap | Get a 7-Day Free Trial | 10.66 | 661.69 | 252.20 | 62.55 | 66.12 | ||||||||||||||
| Cardiff Oncology Quarterly Data | ||||||||||||||||||||
| Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
| Market Cap | Get a 7-Day Free Trial | 73.72 | 65.68 | 62.10 | 66.12 | 238.75 | ||||||||||||||
Competitive Comparison of Cardiff Oncology's Market Cap
For the Biotechnology subindustry, Cardiff Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Market Cap falls into.
Cardiff Oncology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cardiff Oncology's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
| Market Cap (A: Dec. 2023 ) | = | Share Price (A: Dec. 2023 ) | * | Shares Outstanding (EOP) (A: Dec. 2023 ) |
| = | $1.48 | * | 44.677 | |
| = | $66.12 |
Cardiff Oncology's Market Cap for the quarter that ended in Mar. 2024 is calculated as
| Market Cap (Q: Mar. 2024 ) | = | Share Price (Q: Mar. 2024 ) | * | Shares Outstanding (EOP) (Q: Mar. 2024 ) |
| = | $5.34 | * | 44.71 | |
| = | $238.75 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology(NAS:CRDF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cardiff Oncology Market Cap Related Terms
Thank you for viewing the detailed overview of Cardiff Oncology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Cardiff Oncology (Cardiff Oncology) Business Description
Industry
GURUFOCUS.COM »STOCK LIST »Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Market Cap
Comparable Companies
SABS IMUX SRNEQ OCUP KZR ANEB HRGN AVRO NKGN INAB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
XE7C:Germany
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Website
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
Executives
| Gary W Pace | director | C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857 |
| Fairooz Kabbinavar | officer: Chief Medical Officer | C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121 |
| Mark Erlander | officer: Chief Scientific Officer | C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121 |
| Lale White | director | 310 GODDARD, SUITE 150, IRVINE CA 92618 |
| James O Armitage | director | C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451 |
| James E. Levine | officer: Chief Financial Officer | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
| Renee P Tannenbaum | director | 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054 |
| Tod Smeal | officer: Chief Scientific Officer | 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121 |
| Katherine L Ruffner | officer: Chief Medical Officer | 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121 |
| Mani Mohindru | director | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902 |
| Rodney S Markin | director | C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135 |
| Gary S Jacob | director | |
| Vicki Kelemen | officer: Exec. VP and COO | 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121 |
| John P Brancaccio | director | C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852 |
| Rajeev M. Shah | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Cardiff Oncology (Cardiff Oncology) Headlines
From GuruFocus
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
By PRNewswire • 10-26-2023
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
By PRNewswire PRNewswire • 03-02-2023
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
By PRNewswire PRNewswire • 03-28-2023
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
By PRNewswire • 01-17-2024
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
By PRNewswire • 06-21-2023
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
By PRNewswire PRNewswire • 11-03-2022
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
By PRNewswire • 11-20-2023
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
By PRNewswire • 09-26-2023
Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates
By PRNewswire PRNewswire • 07-05-2022
Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates
By PRNewswire PRNewswire • 08-04-2022
